Discovery/R&D

  1. Emerging From Stealth With Vima Therapeutics' Bernard Ravina, M.D. 10/31/2025

    On this week's episode of the Business of Biotech, we're speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May with $60 million Series A financing to develop an oral candidate for dystonia, a movement disorder.

  2. Changing The Diabetes Care Paradigm With Arecor's Dr. Sarah Howell 7/21/2022

    While renal disease treatment technologies have seen moderate incremental improvements, there hasn't been a step-change advance in diabetes care since the discovery of insulin more than 100 years ago. Working with manufacturers of existing diabetes therapeutics in addition to advancing its own pipeline, Arecor is developing enhanced reformulations of tried-and-true therapeutics like insulin to improve a long-static standard of care. Arecor CEO Sarah Howell, Ph.D. joins the Business of Biotech for a discussion on the company's approach to improving the quality of life for some 200 million insulin-dependent patients worldwide.

  3. Building A DNA Delivery System With Poseida Tx CEO Eric Ostertag, M.D., Ph.D. 9/27/2021

    Eric Ostertag, M.D., Ph.D., wanted to launch a biotech. When University of Pennsylvania department heads said no to a licensing deal for lack of a CEO, Dr. Ostertag convinced them he could run the company. Many bold moves later, Dr. Ostertag is founder and CEO at Poseida Therapeutics, a company that's doing things never seen before in the field of CAR T-cell and gene therapies for multiple myeloma and prostate cancer. On this week's episode of The Business of Biotech, Dr. Ostertag gives us a tour of the architecture supporting Poseida's unique 3-tiered development and manufacturing platform.

  4. Building An Efficient Biopharma With South Rampart Pharma's Hernan Bazan, M.D. 7/16/2025

    On this week's Business of Biotech, Dr. Hernan Bazan, M.D., co-founder and CEO at New Orleans-based South Rampart Pharma, talks about building an ultra-lean drug development company to address an unmet need observed in his own patients as a surgeon: safe treatments for acute pain.

  5. Real-Time Clinical Analysis With Glympse Bio's Dr. Caroline Loew 6/1/2021

    On this episode of the Business of Biotech, we're going deep with Glympse Bio President & CEO Dr. Caroline Loew to explore the possibilities and implications of the in-vivo, bioengineered, tunable sensors the company is developing for diagnostic and prognostic purposes in protease-mediates diseases. Currently in the clinic with applications for Non-Alcoholic Steatohepatitis and other fibrotic diseases as well as Non-Small Cell Lung Cancer and other solid tumors, Glympse is unlocking an unprecedented view of near-real-time therapeutic response and therapeutic efficacy that could have big implications on the way biologics are developed, refined, and studied in the clinic.

  6. Off-The-Shelf CAR T-Cell Therapy? 10/26/2020

    Find out what drove John McKearn, Ph.D. & CEO at Wugen, out of the lab at Pfizer and on to his quest to develop off-the-shelf cell therapies for T-Cell leukemias and lymphomas, Acute Myeloid Leukemia, and Multiple Myeloma.

  7. Therapeutic Molecules From Moss with eleva's Andreas Schaaf And Björn Cochlovius, Ph.D. 4/20/2023

    We kick this conversation off with the writer Elizabeth Gilbert's take on moss, which she so eloquently dubs a "resurrection engine." Gilbert almost certainly didn't realize the potential of moss to play a resurrectional role in human health, but Eleva Biotech's Andreas Schaaf and Björn Cochlovius do. On this episode of the Business of Biotech, we learn about a company that's developing proteins to fuel its own pipeline — and its partners' — from a most ubiquitous plant that grows virtually everywhere. It grows particularly well in bioreactors outfitted with custom grow lights and presents some significant advantages over CHO cell line development.

  8. Engineering B Cells With Immusoft's Sean Ainsworth 12/5/2025

    On this week's episode of the Business of Biotech, Sean Ainsworth, CEO and Chairman at Immusoft, talks about transitioning from the research bench to entrepreneurship, his M&A experiences as a biotech founder, and why engineered B cell therapies offer a better, more patient-friendly administration for lysosomal storage diseases currently treated with enzyme replacement therapies.

  9. Precision Radiopharmaceuticals with Ratio's Jack Hoppin, Ph.D. 2/21/2024

    Multimodal approaches to the delivery of radiologically active compounds have created a fertile environment for players in the space to put on a precision medicine clinic, so to speak. What’s more, Radiopharmaceuticals create a unique business opportunity given the closely related and necessary companion diagnostic arena.

  10. Drug Development: From Bench To Bedside With Allan Shaw 5/10/2021

    CFO to the biopharma stars and frequent Business of Biotech guest Allan Shaw joins us for a candid discussion on the keys to efficiency as you move your candidate from the bench to the bedside. Shaw shares the common perils of insular thinking in biopharma and offers practical advice for avoiding those pitfalls. We discuss the value of being early in the context of the current biopharma market — early to study, early to differentiate, early to kill if necessary, and early to fund your project on its journey to the clinic.